Bristol Myers Squibb (BMS) has just announced that they will extend the “Melody” compassionate access program for those patients with metastatic melanoma to allow patients access where there is limited or no private insurance coverage until April 1st, 2019. While we are patiently waiting for final price negotiations to conclude and then potential provincial listing and coverage, this extension will help a significant number of metastatic patients. Thank you to BMS, Annette Cyr and everyone who worked hard to allow Canadians equal access to this life saving drug treatment.
